Zhongsheng Pharma subsidiary advances RAY1225 for MASH treatment

Guangdong Zhongsheng Pharmaceutical's controlling subsidiary, Zhongsheng Ruichuang Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for a new indication clinical trial of its self-developed Class I innovative polypeptide drug, RAY1225 injection. The drug will be investigated for the treatment of metabolic-associated steatohepatitis (MASH).

The clinical trial application, accepted on September 26, 2025, received approval to proceed with clinical trials for the new MASH indication. This approval is supported by multiple acceptance and notification numbers.

RAY1225 injection is an innovative structural polypeptide drug with global intellectual property rights, developed by Zhongsheng Ruichuang. It exhibits dual agonistic activity on GLP-1 and GIP receptors, demonstrating potential for long-acting treatment with bi-weekly injections. Currently, the drug is also undergoing Phase III clinical trials for the treatment of obesity/overweight in China and for Type 2 diabetes. The company highlighted that MASH is a significant unmet medical need, and RAY1225’s preclinical studies have shown promise in improving NAS scores and reducing body weight in MASH animal models.